Alternate Title
Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outcomes
Outline
Trial Contact Information
Registry Information

Alternate Title

Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients Who Have Multiple Myeloma or Primary Systemic Amyloidosis

Basic Trial Information

Phase	Type	Status	Age	Sponsor	Protocol IDs
Phase II	Treatment	Completed	18 and over	NCI	CPMC-IRB-7328 CPMC-CAMP-009, NCI-G00-1882, NCT00007995

Objectives

1. Determine the response rate in patients with multiple myeloma or primary systemic amyloidosis treated with high-dose chemotherapy with autologous hematopoietic stem cell support.
2. Determine the toxicity of this regimen in these patients.
3. Determine the disease-free survival and overall survival of patients with multiple myeloma treated with this regimen.

Entry Criteria

Disease Characteristics:

• Histologically confirmed multiple myeloma

  OR




• Primary systemic amyloidosis resulting in significant organ dysfunction and decreased quality of life



• Complete or partial response after standard chemotherapy



• Primary refractory or relapsed multiple myeloma after first-line treatment with standard chemotherapy



• Ineligible for higher priority national or institutional clinical studies

Prior/Concurrent Therapy:

Biologic therapy:

• Concurrent participation in gene therapy trials allowed

Chemotherapy:

• See Disease Characteristics
• No other concurrent chemotherapy

Endocrine therapy:

• No concurrent steroids as antiemetics during chemotherapy
• No concurrent anticancer hormonal therapy

Radiotherapy:

• Not specified

Surgery:

• Not specified

Other:

• No concurrent barbiturates or acetaminophen during chemotherapy
• Concurrent participation in supportive care trials allowed

Patient Characteristics:

Age:

• 18 and over

Performance status:

• ECOG 0-2

Life expectancy:

• Not specified

Hematopoietic:

• Not specified

Hepatic:

• Bilirubin less than 2 times normal

Renal:

• Creatinine less than 2.5 mg/dL or on stable hemodialysis

Cardiovascular:

• LVEF at least 45%

Pulmonary:

• DLCO at least 60% of predicted

  OR

• Approval by pulmonologist

Other:

• HIV negative

Expected Enrollment

Approximately 60-75 patients (25 for responsive disease stratum, 25 for refractory or relapsed disease stratum, and 10-25 for primary systemic amyloidosis stratum) will be accrued for this study within 3 years.

Outcomes

Disease-free survival at 2 years (patients with responsive disease)

Duration of hematologic toxicity
Time to an absolute neutrophil count
Platelet independence

Outline

Patients are stratified according to disease response to prior treatment (responsive vs refractory or relapsed) and diagnosis (multiple myeloma vs primary systemic amyloidosis).

Following a course of induction chemotherapy, patients receive filgrastim (G-CSF) subcutaneously (SC) daily until the completion of peripheral blood stem cell (PBSC) harvesting. Patient who do not mobilize sufficient cells undergo bone marrow harvest.

Patients receive melphalan IV over 30 minutes on days -2 and -1. Half of the stored PBSCs and/or bone marrow is reinfused on day 0. Patients receive sargramostim (GM-CSF) daily beginning on day 0 and continuing until blood counts recover. Patients with primary systemic amyloidosis who are not responding to or are unable to tolerate treatment do not proceed to the second course of therapy.

Within 4-6 weeks after receiving melphalan, patients receive oral busulfan on days -8 to -5 followed by cyclophosphamide IV continuously on days -4 and -3. The remaining half of PBSCs and/or bone marrow is reinfused on day 0. Patients receive GM-CSF daily beginning on day 0 and continuing until blood counts recover.

Within 4-12 weeks after receiving the second course of high-dose chemotherapy, multiple myeloma patients receive maintenance therapy consisting of interferon alfa SC 3 days a week, after blood counts recover.

Patients are followed every 3 months for 1 year and then annually for 5 years.

Trial Contact Information

Trial Lead Organizations

Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center

Charles Hesdorffer, MD, Protocol chair		Ph: 212-305-4907 Email: csh1@columbia.edu

Registry Information
Official Title		Phase 2 Study Of High Dose Chemotherapy Followed By Autologous Hematopoietic Stem Cell Support In Patients With Multiple Myeloma And Primary Light Chain Amyloidosis
Trial Start Date		1999-07-28
Trial Completion Date		2007-11-29
Registered in ClinicalTrials.gov		NCT00007995
Date Submitted to PDQ		2000-11-06
Information Last Verified		2007-07-11
NCI Grant/Contract Number		CA13696

Back to Top